Author: Dr. Chitra Lele, Sciformix Corporation
Thanks to increased scrutiny of potential patient health risks and the increasing involvement in emerging markets, pharmaceutical manufacturers’ priorities and approaches are shifting. In the not-so-distant future, it seems that comparative benefit-risk assessment will become the primary driver of clinical decision-making. Huge advances in biology and the life sciences have deepened and improved our understanding of disease mechanisms, and, with stakeholders becoming increasingly aware of the challenges being faced by the healthcare industry, there is an increasing opportunity and need for change. Along with this increased awareness comes a greater need to understand the effect of medicines on individual patient responses, and ensuring that all therapies are acting in a safe, efficient manner.
In order to deliver this level of safety, proactive risk management is becoming ever more critical. By improving the capture, analysis and dissemination of medical, clinical and epidemiological data, pharmaceutical manufacturers can implement proactive management of safety and benefit-risk balance of new and established healthcare products.